retatrutide trial results today New Phase 3 retatrutide data just dropped π Eli Lilly's trial reported Tirzepatide vs. Retatrutide | AlphaMan
Description
X.VegaN.RieussetJ.et al
doi: 10.1001/jamainternmed.2013.2720 221 KnapenLMvan DalemJKeulemansYCvan ErpNPBazelierMTDe BruinMLet al
Available from: Fletcher AL, Lowen TE, Sakkal S, Reiseger JJ, Hammett MV, Seach N, et al
Starting with the lowest approved dose and increasing slowly often helps minimize adverse reactions
Main text Modern GLP-1 receptor agonists and co-agonists (GLP-1 medicines) such as liraglutide, dulaglutide semaglutide, and the GLP-1R/glucose dependent insulinotropic polypeptide receptor (GIPR) co-agonist tirzepatide, were initially developed for the treatment of type 2 diabetes (T2D) due to their actions to increase insulin and decrease glucagon secretion and slow gastric emptying through effects on the pancreas and brain
